- Email: [email protected]
PDL1 blockade in metastatic bladder cancer
Annals of Oncology 26 (Supplement 2): ii2, 2015 doi:10.1093/annonc/mdv080.2
Plenary session 2: New frontiers in immunotherapy (1): Checkpoint targets O2:2
PDL1 BLOCKADE IN METASTATIC BLADDER CANCER
T. Powles Bart Cancer Institute, London, United Kingdom
The outcome of patients with urothelial bladder cancer is poor. No new treatment have been introduced into the clinic for a generation. Recent data has demonstrated significant activity of immune checkpoint inhibitors in heavily pretreated metastatic disease. Activity was particularly marked in tumors which over express PD-L1. The drugs appear well tolerated and responses were long lasting. This has resulted in a number of potentially practice changing studies which are ongoing and breakthrough FDA designation for MPDL3280A. Prominent questions for the future include1) better defining patients who benefit from therapy, 2) the role of combinations of therapy and 3) the optimal clinical space for drug development.
abstracts
Downloaded from http://annonc.oxfordjournals.org/ by guest on March 23, 2016
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Plenary session 2: New frontiers in immunotherapy (1): Checkpoint targets O2:2
PDL1 BLOCKADE IN METASTATIC BLADDER CANCER
T. Powles Bart Cancer Institute, London, United Kingdom
The outcome of patients with urothelial bladder cancer is poor. No new treatment have been introduced into the clinic for a generation. Recent data has demonstrated significant activity of immune checkpoint inhibitors in heavily pretreated metastatic disease. Activity was particularly marked in tumors which over express PD-L1. The drugs appear well tolerated and responses were long lasting. This has resulted in a number of potentially practice changing studies which are ongoing and breakthrough FDA designation for MPDL3280A. Prominent questions for the future include1) better defining patients who benefit from therapy, 2) the role of combinations of therapy and 3) the optimal clinical space for drug development.
abstracts
Downloaded from http://annonc.oxfordjournals.org/ by guest on March 23, 2016
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].